fbpx

Massive Bio Partners with Biden Cancer Initiative

OCTIC is a shared platform where all information about clinical trials can be stored and accessed for patient matching and other data mining. The system will employ a single set of terms and rules, plus a user-friendly interface for biopharma companies to readily enter and update their trials. Nine organizations join forces with the Biden Cancer Initiative to make clinical trial information available, paving the way for improved trial matching technology and servicesFounding members are Massive Bio, BreastCancerTrials.org, Cancer Commons, Ciitizen, EmergingMed, GenomOncology, Sarah Cannon Research Institute, IBM Watson Health, and Syapse. The announcement was made at the Annual meeting of American Society of Clinical Oncology (ASCO) in Chicago on June 1, 2019.

Read full press release

Press Releases

Leave a Comment

Your email address will not be published. Required fields are marked *

Previous reading
Massive Bio Partners with Biden Cancer Initiative
Next reading
In the Search of AI for Oncology